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Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA
are at risk of inflammation of the uvea in the eye (uveitis). Overall, 20% to 25% of paediatric uveitis is associated
with JIA. Major risk factors for development of uveitis in JIA are oligoarticular pattern of arthritis, an age at onset of
arthritis of less than seven years of age, and antinuclear antibody positivity. In the initial stages of mild to moderate
inflammation the uveitis is asymptomatic. This has led to current practice of screening all children with JIA for
uveitis. Approximately 12% to 38% of patients with JIA develop uveitis in seven years following onset of arthritis. In
30% to 50% of children with JIA-associated uveitis structural complications are present at diagnosis. Furthermore
about 50% to 75% of those with severe uveitis will eventually develop visual impairment secondary to ocular
complications such as cataract and glaucoma. Defining the severity of inflammation and structural complications in
uveitis patients is now possible following Standardised Uveitis Nomenclature (SUN) guidelines, and modified to
incorporate the consensus of end point and outcome criteria into the design of randomised trials. Despite current
screening and therapeutic options (pre-biologics) 10% to 15% of children with JIA-associated uveitis may develop
bilateral visual impairment and certified legally blind. To date, there remains no controlled trial evidence of benefits
of biologic therapy.
Methods/design: This study will randomise 154 patients aged 2 to 18 years with active JIA-associated uveitis
(despite methotrexate (MTX) treatment for at least 12 weeks). All participants will be treated for 18 months, with
follow up of 3 years from randomisation (continuing on MTX throughout). All participants will receive a stable dose
of MTX and in addition either adalimumab (20 mg/0.8 ml for patients <30 kg or 40 mg/0.8 ml for patients weighing
30 kg or more, subcutaneous (s/c) injection every 2 weeks based on body weight), or placebo (0.8 ml as appropriate
according to body weight) s/c injection every 2 weeks.
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Discussion: This is the first randomised controlled trial that will assess the clinical effectiveness, safety and cost
effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis
associated uveitis.
Trial registration: ISRCTN10065623
Keywords: Adalimumab, Juvenile idiopathic arthritis, Methotrexate, Ophthalmology, Paediatric, Rheumatology,
Safety, UveitisBackground
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in children. Children with JIA also are at
risk of inflammation of the uvea in the eye (uveitis). Over-
all, 20% to 25% of all paediatric uveitis is associated with
JIA [1,2], but a greater proportion is seen in referral
cohorts. The major risk factors for the development of
uveitis in JIA patients are oligoarticular pattern of arthritis,
age at onset of arthritis younger than 7 years and antinu-
clear antibody positivity [3]. In the initial stages of mild to
moderate inflammation, uveitis is entirely asymptomatic.
This has led to the current practice of screening all chil-
dren with JIA regularly for uveitis. Approximately 12% to
38% of patients with JIA will develop uveitis in the 7 years
following the onset of arthritis [4,5]. In 30% to 50% of chil-
dren with JIA-associated uveitis, structural complications
are present at the time of diagnosis [6]. Furthermore, about
50% to 75% of those with severe uveitis will eventually
develop visual impairment secondary to ocular complica-
tions such as cataract, glaucoma, band keratopathy and
macular pathology [7-9].
Defining the severity of inflammation and structural
complications in uveitis patients can now be more con-
sistently described by following Standardised Uveitis No-
menclature (SUN) guidelines and incorporating them
into the design of randomised controlled trials (RCTs)
and cohort studies [10]. Significant poor prognosticators
of poor visual acuity include structural changes at pres-
entation, the need for intraocular surgery, posterior seg-
ment inflammation, abnormal intraocular pressure and
failure to maintain long-term disease control as marked
by persistent anterior chamber (AC) cell scores of 1 or
higher [6-8,11]. Despite current screening and thera-
peutic options (prebiologics), 10% to 15% of children
with JIA-associated uveitis may eventually develop bilat-
eral visual impairment and become certified legally blind
[12,13]. It is therefore critical to find more effective
therapeutic interventions for them.
Rationale
Methotrexate (MTX) is well-established as the first-line
disease-modifyin\g agent in the management of JIA
[14,15]. The current approaches to the treatment of mildJIA-associated uveitis include use of topical steroids.
MTX is also thought to be effective for JIA-associated
uveitis in children with moderate to severe uveitis
[16-18], but there have been no prospective, randomised,
placebo-controlled trials of MTX or steroid regimens in
JIA-associated uveitis. Systematic review of the evidence
for the effectiveness of MTX in JIA patients is restricted
to joint involvement [14], but not in paediatric uveitis.
Despite the scarce evidence, MTX has become the main-
stay of treatment for JIA-associated uveitis [19]. How-
ever, about 15% to 50% of affected children will have
refractory uveitis in spite of optimal therapy with MTX
[16-18]. De Boer et al. [13] found that uveitis was not
controlled in 30% of patients started on MTX during the
first year of therapy and that, even when remission was
achieved with MTX, 9 of 13 later relapsed and only 4
(18%) of 22 patients achieved total remission. In the
Great Ormond Street cohort, a similarly low proportion
of 12% were found to be in total remission 5 years after
initiation of MTX therapy [20]. Several agents, including
ciclosporin and mycophenolate mofetil (MMF), have
been shown to be of benefit in controlling JIA-associated
uveitis in small retrospective case series [21,22]. However,
their use remains restricted because of intolerability due
to adverse reactions and little evidence that they rescue
MTX-refractory patients. In addition, neither ciclosporin
nor MMF is very effective in controlling joint manifesta-
tions in children [19]. More recently, animal models and
corroborative human evidence [23] support the role of
tumour necrosis factor α (TNF-α) in the aetiopathogen-
esis of uveitis and, moreover, the potential value of inhi-
biting TNF-α as a therapeutic intervention [24].
Studies utilising experimental models of autoimmune
uveitis have demonstrated that TNF-α plays a pivotal
role in the pathogenesis of intraocular inflammation
[23], which has been borne out in the treatment of adult
uveitis [24]. In mouse models of anterior uveitis, deleting
the p55 receptor, as well as combined TNF receptor
(TNFR) p55- and p75-knockout animals, resulted in
reduced disease [25] more significantly than the effect of
TNFR p55 fusion protein [26]. Furthermore, in an ani-
mal model of uveitis, infliximab reduced disease severity
[27], albeit at doses of 20 mg/kg. Translating these data
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have demonstrated the efficacy of anti-TNF-α therapies,
including infliximab and adalimumab, in the treatment of
severe refractory uveitis in adults and children [28-33]. In
contrast, etanercept has been reported not to halt the on-
set of uveitis or to be more effective than placebo [34,35].
It also has been shown to be less effective than infliximab
in treating JIA-associated uveitis [31,36,37]. A number of
reports of new-onset uveitis associated with etanercept
use in JIA have been published [38]. Investigators in an
AE register–based study who examined these cases
determined that whilst the frequency was greater for
etanercept than for infliximab or adalimumab (n = 20;
four and two cases, respectively), causality could not be
established [39]. Etanercept is not considered to be ef-
fective in treating intraocular inflammation [31].
Adalimumab is a fully human monoclonal antibody
engineered by gene technology that uses site-directed
mutagenesis to enhance its binding efficiency to TNF-α.
It does not contain nonhuman or artificial protein se-
quences. Adalimumab binds only to TNF-α and has a
half-life of approximately 2 weeks. The antibody has been
studied extensively in vitro and in vivo and has been
shown not to be toxic in animal toxicology experiments.
A clinical trial of adalimumab as monotherapy or in com-
bination with MTX in adult patients with rheumatoid
arthritis showed a significant clinical response [40]. A
multicentre, randomised, double-blind, stratified parallel
group trial showed a significant benefit in children with
active JIA [41].
Retrospective case series in paediatric noninfectious
uveitis treated with adalimumab have shown very prom-
ising results, with 21 of 26 eyes from among 14 children
with JIA-associated or idiopathic uveitis showing im-
provement in inflammation [42]. In another retrospective
case series of 18 paediatric patients with uveitis, 88% had
a substantial decrease in ocular inflammation, and adali-
mumab showed corticosteroid-sparing potential [28].
To the best of our knowledge, no prospective studies of
the efficacy and safety of anti-TNF agents in JIA-associated
uveitis have been conducted to date. In the RCT of adali-
mumab in JIA that demonstrated safety and efficacy, the
most commonly reported AEs were infections and injec-
tion site reactions [41]. SAEs considered possibly related
to the study drug by the investigators occurred in 14
patients. Seven of these AEs included one case of bron-
chopneumonia, herpes simplex infection, pharyngitis and
pneumonia, and there were two cases of herpes zoster
infection. In that trial, there were no deaths, malignant
conditions, opportunistic infections, cases of tuberculosis
(TB), demyelinating diseases or lupus-like reactions [41].
The fixed-dose model of 20 mg for children weighing
<30 kg and 40 mg for children weighing ≥30 kg selected
for our current SYCAMORE Trial is based on the datagenerated in the above Lovell et al. trial using the same
dosing regimen [41].
Potential risks and benefits
JIA-associated uveitis is a severe, potentially sight-
threatening condition that is often inadequately treated
using standard therapies. The advent of biologic therapies
offers significant anticipated benefits. However, due care
must be taken in determining the potential benefits of
anti-TNF therapy, which is now being used off-label for
this condition, against the potential associated risks. The
safety (short- and long-term) of the new biologic therapies
in children and young people is of major importance, par-
ticularly in our present study. The risk-to-benefit assess-
ment of this intervention needs careful attention. Safety is
therefore a key secondary outcome measure of the trial.
Potential risks
The long-term follow-up of children on etanercept and
adalimumab therapy described in the controlled studies
published to date have not shown any increased risk of ma-
lignancies. However, the US Food and Drug Administration
(FDA) recently issued an alert to healthcare professionals
that its analysis has revealed that 48 children developed
malignancies whilst on anti-TNF agents, and 11 of the
children died [43]. The data are derived mainly from chil-
dren and adolescents on etanercept and infliximab therapy;
data on adalimumab are scarce because of limited follow-
up. The analysis includes, in particular, children with
Crohn’s disease. Of the 48 children, 88% were taking
concomitant immunosuppressive medication, including
azathioprine and MTX. The complete details of the FDA
analysis are not currently available. Importantly, these data
do not provide comparative information on long-term ma-
lignancy rates in JIA patients treated with MTX alone or in
patients with untreated JIA. Subsequently, a presentation at
the American College of Rheumatology (ACR)/Associate
Rheumatology Health Professional 2009 Annual Scientific
Meeting reported that in 1,168 patients over 16,396
patient-years, no increased risk of anti-TNF therapy in JIA
patients was found [44]. Recent data presented at the
European League Against Rheumatism emphasises the
importance of comparing anti-TNF safety data to un-
treated disease [45] and that current data do not indicate
a significant relative increase with respect to controls
[46]. All these reports, however, emphasise the critical
importance of making safety a major priority in this trial.
This priority is both within the treatment and follow-up
duration of the trial, but procedures are also in place to
continue this safety follow-up for the longer term.
The risk of increased malignancy with azathioprine in pa-
tients with Crohn’s disease on infliximab is well-recognised
[47,48]. As noted already, AEs associated with the recent
adalimumab trial in JIA were associated with minimal
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uated overall mortality and cancer mortality in relation to
immunosuppressive drug exposure, including anti-TNF
drugs, in adult patients with ocular inflammatory diseases
[49]. The study did show an increased overall and cancer
mortality in adult patients exposed to anti-TNF agents.
The study’s authors acknowledge that these data need to
be interpreted with caution because of the methodo-
logical issues associated with retrospective studies and
the prevalence of comorbidity in patients taking anti-
TNF drugs.
On the basis of adult patient data, as well as on the
growing evidence base of published data derived from
long-term follow-up in biologic registries, clinical trials
and cohort studies, a number of important safety signals
need to be considered in this trial. Patients taking TNF
blockers are more susceptible to serious infections. Pa-
tients must therefore be monitored closely for infections,
including TB, before, during and after treatment with
adalimumab. Because the elimination of adalimumab
may take up to 5 months, monitoring should be contin-
ued throughout this period.
AEs of the haematologic system, including medically
significant cytopaenia (for example, thrombocytopaenia,
leucopaenia) have been reported with adalimumab. All
patients should be advised to seek immediate medical at-
tention if they develop signs and symptoms suggestive of
blood dyscrasias (for example, persistent fever, bruising,
bleeding, pallor) while on adalimumab.
Adalimumab monotherapy, as well as concomitantly
with MTX, has been studied in rheumatoid arthritis,
polyarticular JIA and psoriatic arthritis patients [41].
Antibody formation to adalimumab itself was lower
when adalimumab was given together with MTX com-
pared to adalimumab monotherapy. Administration of
adalimumab without MTX resulted in increased forma-
tion of antibodies, increased clearance and reduced effi-
cacy of adalimumab. In patients with polyarticular JIA,
adalimumab antibodies were identified in 27 (15.8%) of
171 patients treated with adalimumab. In patients not
given concomitant MTX, the incidence of adalimumab
antibodies was 22 (25.6%) of 86, compared to 5 (5.9%) of
85 when adalimumab was used as an add-on to MTX.
Patients who develop a new infection while undergoing
treatment with adalimumab should be monitored closely
and should undergo a complete diagnostic evaluation.
Administration of adalimumab should be discontinued if
a patient develops a new serious infection or sepsis, and
appropriate antimicrobial or antifungal therapy should be
initiated until the infection is controlled. Physicians
should exercise caution when considering the use of ada-
limumab in patients with a history of recurring infection
or with underlying conditions which may predispose
them to infections, including the use of concomitantimmunosuppressive medications. Serious infections seen
in clinical trials include pneumonia, pyelonephritis, septic
arthritis and septicaemia.Known potential benefits
In rheumatoid arthritis phases I to IV studies [50], all indi-
vidual components of the adult ACR response criteria
(number of tender and swollen joints, physician and pa-
tient assessment of disease activity and pain, disability
index Health Assessment Questionnaire scores and C-
reactive protein (mg/dl) levels) improved at 24 or 26 weeks
compared to placebo. In these studies, adalimumab-treated
patients achieved statistically significant improvement in
their rheumatoid arthritis symptoms based on ACR criteria
showing 20% improvement (ACR20) and ACR50 responses
compared to placebo as early as 1 to 2 weeks after initi-
ation of treatment.
In polyarticular course JIA, adalimumab has been shown
to have a significant clinical benefit in improving JIA on
the basis of core paediatric ACR response criteria [51]. In
the double-blind withdrawal design phase of the trial of
adalimumab in JIA patients [41], amongst patients not
receiving MTX, there was a significant increase in the
number of disease flares in those patients who subse-
quently received placebo compared to those given adali-
mumab (71% vs. 43%; P = 0.03) [52]. In those patients
receiving concomitant MTX, flares occurred in 65% on
placebo compared to 37% who received adalimumab (P =
0.02). At 48 weeks, the percentage of patients treated with
MTX who had ACR Pediatric 30 response criteria
(Pedi 30), Pedi 50, Pedi 70 and Pedi 90 responses was
significantly greater for those treated with adalimumab
than for those given placebo (ACR Pedi 30: 63% vs.
38%, P = 0.03; ACR Pedi 50: 63% vs. 38%, P = 0.03; ACR
Pedi 70: 63% vs. 27%, P = 0.002). Open-label extension
of the studies showed sustained responses for up to
104 weeks of treatment. As outlined in the protocol
rationale, its reported use in JIA-associated uveitis
warrants a RCT trial to assess its clinical effectiveness
and safety.Methods/design
Trial design
The SYCAMORE Trial will randomise 154 patients ages
2 to 18 years with active JIA-associated uveitis (despite
MTX treatment for at least 12 weeks). All participants
will be treated for 18 months, with follow-up of 3 years
from randomisation (continuing on MTX throughout).
All participants will receive a stable dose of MTX as well
as either adalimumab (20 mg/0.8 ml for patients <30 kg
or 40 mg/0.8 ml for patients weighing 30 kg or more,
subcutaneous injection every 2 weeks based on body
weight) or placebo (0.8 ml as appropriate according to
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Figure 1 shows the schematic of trial design.
Regulatory approval
Full ethical approval was granted by the London Hamp-
stead Research Ethics Committee (11/LO/0425). Full ap-
proval also was given by the Medicines and Healthcare
Products Regulatory Agency (EudraCT 2010-021141-41).
Primary end point
The primary end point of the study is ‘time to treatment
failure’. Treatment failure is defined by one or more of
the following factors:Participant fulfilling eligibility
fully informed writt
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measured over two consecutive readings (grade 1
or 2) still present after 6 months of therapy
In addition, following at least 3 months of therapy,
treatment failure is met if any of the following
factors are met:
2. Use of concomitant medications: at any time,
requirement for concomitant medications in a
manner outside predefined acceptable criteria or for
any of the concomitant medications not allowed
3. Intermittent or continuous suspension of study
treatment (adalimumab or placebo) for a cumulative
period longer than 4 weeks
Ocular comorbidities are defined as follows: (1) disc
swelling and/or cystoid macular oedema as gauged clinic-
ally and, where possible, by optical coherence tomog-
raphy (OCT); and/or (2) raised intraocular pressure
(>25 mmHg) sustained over two consecutive visits with-
out any response to a single ocular hypotensive agent;
and/or (3) hypotony (<6 mmHg) sustained over two con-
secutive visits; and/or (4) development of unexplained
reduction in vision of 15 letters according to the loga-
rithm of the minimal angle resolution (logMAR) over
two consecutive visits (if the patient has cataracts, they
will remain in the trial, even if cataract surgery is re-
quired; failure will remain as described in the end points
described above).
Where a reading is must be sustained over two consecu-
tive visits to define treatment failure, the time of treatment
failure will be taken as the second of these readings.
Secondary end points
1. Number of participants failing treatment
2. Incremental cost-effectiveness and cost utility of
adalimumab added to MTX compared with MTX alone
3. Health status according to the multiattribute Health
Utility Index Mark 2
4. Safety, tolerability and compliance, defined as
follows:
a. Adverse events (AEs) and serious adverse events
(SAEs)
b. Laboratory parameters (haematological and
biochemical analysis and urinalysis)
c. Development of human antihuman antibody to
adalimumab determined with samples collected at
1, 6 and 18 months
d. Participant diaries and dosing records will
determine tolerability and compliance throughout
the trial treatment period
5. Use of corticosteroids over the duration of the study
period and throughout follow-up, including the
following:a. Total oral corticosteroid dose
b. Reduction and reduction rate of systemic
corticosteroid dose from entry dose
c. Topical corticosteroid use (frequency) compared to
use at time of entry
d. Need for pulsed corticosteroid
6. Optic and ocular outcomes, defined as follows:
a. Number of participants with disease flares
(defined by worsening based on SUN criteria)
following a minimum of 3 months of disease
control
b. Number of participants with disease flares within
the first 3 months of the study
c. Visual acuity as measured by age-appropriate
logMAR assessment
d. Number of participants with resolution of
associated optic nerve or macular oedema (as
assessed by slit-lamp biomicroscopy or OCT
(where available)
e. Number of participants with disease control
(defined as zero cells with topical treatment for 3
and 6 months)
f. Number of participants entering disease
remission (defined as zero cells without topical
treatment for 3 and 6 months)
g. Duration of sustaining inactive disease (zero cells
with or without topical treatment)
7. Quality of life assessments (Childhood Health
Questionnaire and Childhood Health Assessment
Questionnaire)
8. ACR Pedi core set criteria at ACR30, ACR50,
ACR70, ACR90 and ACR100 levels
9. Number of participants with disease flares, in
remission on and off medication [53], related to
their JIA and with minimum disease activity [54]
10. Number of participants requiring change in biologic
and/or disease-modifying antirheumatic drug
therapy for arthritis due to failure to respond
Study population
Inclusion criteria
Participants are eligible for the trial based upon having
at least one eye fulfilling the following eligibility criteria:
1. Children and young people ages 2 years and older
up to and including 18 years of age and fulfilling the
International League Against Rheumatism diagnostic
criteria for JIA (all subgroups with uveitis)
2. At the time of trial screening, participants must have
active anterior uveitis, defined as a sustained grade
of cellular infiltrate in anterior chamber of SUN
criteria grade ≥1+ or more during the preceding 12
weeks of therapy despite MTX and corticosteroid
(both systemic and topical) therapy
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(minimum dose of 10 to 20 mg/m2 with a maximum
dose of 25 mg/participant)
4. Participants must have been on MTX for at least 12
weeks and on a stable dose for 4 weeks prior to the
screening visit; omission of a maximum of 2 weeks
of MTX treatment within these 12 weeks is
acceptable and will not render patients ineligible,
unless the omission occurs within the 4 weeks prior
to the screening visit
5. No disease-modifying immunosuppressive drugs,
other than MTX, in the 4 weeks prior to screening
6. Written informed consent of participants or their
parents or legal guardians, as well as assent where
appropriate
7. Participants and their parents or legal guardians
must be willing and able to comply with protocol
requirements
8. For participants of reproductive potential (males and
females), use of a reliable means of contraception
throughout trial participation; postpubertal females
must have a negative serum pregnancy test within ten
days before receiving the first dose of the trial drug
9. Ability to be randomised and commence the trial
treatment within 2 weeks of the screening visit
Exclusion criteria
The following are the exclusion criteria:
1. Uveitis without a diagnosis of JIA
2. Currently on adalimumab therapy or previous
adalimumab treatment
3. Treated with another biologic agent within the
previous five half-lives of the agent
4. More than six topical steroid eye drops per day prior
to screening (This dose must have been stable for at
least 4 weeks prior to the screening visit.)
5. Patients on prednisone or a prednisone equivalent,
change of dose within 30 days prior to screening
6. Patients on prednisone or a prednisone equivalent at
a dose >0.2 mg/kg/day
7. Intraarticular joint injections within 4 weeks prior to
screening
8. Any ongoing chronic or active infection (including
infective uveitis), any major episode of infection
requiring hospitalisation or any treatment with
intravenous antibiotics within 30 days or oral
antibiotics within 14 days prior to the screening
evaluation
9. History of active TB requiring less than 6 months of
treatment or history of untreated latent TB
10. History of central nervous system (CNS) neoplasm,
active CNS infection, demyelinating disease or any
progressive or degenerative neurological disease11. Poorly controlled diabetes or persistent, poorly
controlled, severe hypertension (>95th percentile for
height and age) as determined by the treating physician
12. Previous history of malignancy
13. Intraocular surgery within the 3 months prior to
screening (cataract, glaucoma or vitrectomy)
14. Intraocular or periocular corticosteroids within 30
days prior to screening
15. History of ocular herpetic disease
16. Pregnant or nursing female
17. Demonstration of clinically significant deviations in
any of the following laboratory parameters:
a. Platelet count <100,000/mm3
b. Total white blood cell count <4,000 cells/mm3
c. Neutrophils <1,000 cells/mm3
d. Aspartate aminotransferase or alanine
aminotransferase more than twice the upper limit
of normal (ULN) or serum bilirubin more than
twice the ULN
e. Glomerular filtration rate (GFR) <90 ml/min/
1.73 m2 (GFR (ml/min/1.73 m2 bovine serum
albumin) = 0.55 × height (cm)/plasma creatinine
(mg/dl))
f. Hematocrit <24%
18. Live or attenuated vaccine received within 3
months prior to screening
19. Previous randomisation into either arm of the
SYCAMORE Trial
20. Intraocular pressure <6 mmHg or intraocular
pressure >25 mmHg
21. Intraocular pressure control requiring more than
one topical pressure-lowering therapy or requiring
systemic acetazolamide
Selection of centres/clinicians
The study will be initiated at centres once all their global
requirements (for example, local research and development
(R&D) approval) and study-specific conditions (for ex-
ample, training requirements) have been met and all neces-
sary documents have been returned to the Medicines for
Children Research Network Clinical Trials Unit (MCRN
CTU). Initiation meetings will cover the requirements
outlined in the Clinical Trials Research Centre’s standard
operating procedures related to site training and setup.
Centre/clinician inclusion criteria
The following are the inclusion criteria for centres and
clinicians:
1. Centres offering a combined paediatric
rheumatology/ophthalmology service
2. All participants recruited should have regular and
emergency access to a paediatric rheumatologist
and/or ophthalmologist
Ramanan et al. Trials 2014, 15:14 Page 8 of 13
http://www.trialsjournal.com/content/15/1/143. Completion of calibration training in ophthalmology
assessments
4. Sufficient demonstrated capacity of staff to carry out
study assessments
5. Curriculum vitae (CV), including a record of
International Conference for Harmonisation (ICH)
of Good Clinical Practice (GCP) training of the
Principal Investigator (PI)
6. CV including a record of ICH GCP training of other
personnel on the delegation log
7. Completion and return of the ‘Signature and
Delegation Log’ to the CTU
8. Positive site-specific information
9. Local R&D approval
10. Signed contract between site and sponsor
11. Receipt of evidence of completion of criteria 8 to 10
by CTU
12. Ability to perform biochemical assessments
All sites are expected to demonstrate the ability to run
paediatric clinical trials in accordance with GCP and as
such demonstrate support and infrastructure for all
aspects of trial delivery, including integration of the clin-
ical research teams with pharmacy, clinical laboratory
and research support services. All centres will be ex-
pected to work in collaboration with MCRN CTU sup-
port where present, including the National Institute for
Health Research MCRN local research networks, the
Comprehensive Local Research Network and their equiv-
alents in Scotland, Wales and Northern Ireland.
Centre and clinician exclusion criteria
Centres and clinicians will be excluded if they do not
meet the inclusion criteria and expectations stated above.
Sample size
The sample size is based on data regarding failure rates
from 62 patients on MTX in a comparable population
provided by Dr C Edelsten of Great Ormond Street
Hospital. After 3 months, 11 patients had disease control
based on grade 0 SUN criteria (18%), and therefore, on
the basis of the trial inclusion criteria, they would not be
eligible for inclusion in the trial. At 15 months following
the start of treatment with MTX, 23 patients of the 51
who had failed at 3 months had achieved disease control
(45%), leaving 28 (55%) who had not. The null hypoth-
esis underlying this trial is that there is no significant
difference between adalimumab and placebo in control-
ling disease activity of JIA-associated uveitis unrespon-
sive to MTX therapy.
To detect a relative reduction of 50% between a failure
rate of 60% and 30% with 90% power, at 5% significance
and 2:1 randomisation, a total of 140 patients (93 adali-
mumab and 47 placebo) are required. There is unlikelyto be a trial of this nature again in the near future; there-
fore, we have increased the power of the study to 90%
from the conventional power level of 80% to optimise
the detection of a significant difference between treat-
ment regimens if one truly exists. A trial of adalimumab
in JIA with or without MTX powered the study using a
40% absolute (57% relative) difference in the rate of flare
between the placebo and adalimumab groups [41].
The advent of biological therapies in JIA has led inter-
national investigators to a paradigm shift in the treat-
ment of JIA and its related complications, leading to
significantly more ambitious outcomes in clinical trials,
including elimination of inflammation and normalisation
of short-term and long-term function [15,55]. To this
end, instead of previously accepted clinical outcomes of
30% absolute difference in JIA patient outcomes between
active agent and placebo [56], increasingly significant
differences are being expected and regarded as signifi-
cant, with new definitions of response being established
for use in clinical trials, such as clinical remission and
minimal disease activity [53,54]. Indeed, 40% of patients
in the adalimumab JIA trial were reported as showing an
ACR Pedi 100 response (100% response rate) at 2 years
[41].
The clinically relevant outcomes of JIA-associated uveitis
may take years to develop, and the relationship between
isolated measures of clinical activity and long-term out-
comes remains ill-defined. Recent studies suggest that the
length of continuously controlled activity is likely to be of
more clinical relevance than short-term improvements in
activity levels.
In view of these factors, as well as the expectation
expressed unanimously through consumer consultation
in the development of this trial protocol, we have set a
minimum 50% relative difference in failure rates between
interventions. We estimate that loss to follow-up will be
approximately 10% based on (1) the severe nature of the
disease potentially resulting in loss of vision, (2) clinical
opinion arising from an a priori meeting of investigators
representing participating centres, (3) feedback from
consumer representatives and (4) the exisiting experience
of the investigators and consumer representatives with
compliance with current use of biologic therapies in JIA-
associated uveitis. Therefore, we increased the sample
size by approximately 10%, giving us a total of 154
patients (102 adalimumab and 52 placebo).
Randomisation
Randomisation will be undertaken during normal work-
ing hours (Monday to Friday from 0900 to 1700) by the
pharmacy departments of participating centres upon
receipt of a randomisation request form and prescrip-
tions from authorised clinicians. Pharmacy personnel will
verify that these documents are appropriately completed
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responsible for (1) notifying pharmacy personnel of poten-
tial randomisations so that they can ensure adequate drug
supplies are available on-site and (2) completing the ap-
propriate trial documents and delivering these to the
pharmacy department at their centres so that pharmacy
personnel can proceed with randomisation.
Participants will be randomised using a secure (24-hour)
web-based randomisation programme. Randomisation
lists will be generated at a 2:1 ratio in favour of the active
therapy. The lists will incorporate random elements, and
the web randomisation programme will be controlled cen-
trally by the MCRN CTU. Both measures are being
employed to ensure that participant allocations are con-
cealed. Participant treatment allocation will be displayed
on a secure website, and an automated email confirmation
will be sent to the authorised randomiser. In the event of
an internet connection failure between the centre and the
randomisation system, the centre should contact the
MCRN CTU immediately to try to resolve the problem. If
this is not possible within a reasonable amount of time,
then the supplied backup randomisation envelopes will be
used to provide the treatment allocation.
Assessments and procedures
After written consent (and assent where appropriate)
from the parent or legal guardian or from the trial par-
ticipant, is obtained, medical and ophthalmic histories
will be taken and recorded on the appropriate case report
form (CRF) with particular emphasis on other disorders
of relevance and allergies. Separate sections on the CRF
will be provided to record the JIA and uveitis-specific
medical and ophthalmic histories and the participant’s
other medical and surgical histories. Medication use
(prescriptions, over-the-counter medicines and herbal
supplements) during the 4 weeks prior to the screening
visit will also be recorded. Information from a physical
examination, measures of disease activity and complica-
tions, laboratory tests (haematological and biochemical
analysis and urinalysis) and medication and surgical his-
tories will be gathered at the screening visit and again at
each subsequent trial visit.
Protocol assessments will be performed according to
the table of assessments (Table 1).
With regard to treatment timelines, ‘1-month treatment’
is defined as 4 weeks. After treatment is commenced, the
appointments for each subsequent visit should be made for
4 weeks or 3 months (12 weeks) afterwards, depending on
the visit schedule. An allowance of −7 days or +7 days will
be allowed for monthly visits and −15 days or +15 days for
the 3-month visits. Should unscheduled visits be required
for any reason, they will be recorded on the ‘unscheduled
visit’ CRF. To define treatment failure, there should be an
interval of at least 4 weeks between assessments.Analysis plan
The primary analysis will be carried out according to the
principle of intention to treat all randomised participants
as far as is practically possible. If consent to treatment is
withdrawn but the participant agrees to remain in the
study for follow-up, the participant will be followed until
completion. If the participant decides to withdraw con-
sent completely, however, the reasons for withdrawal of
consent will be recorded (if possible) and reported for
both groups.
The primary outcome is ‘time to failure’. Analysis of
time to treatment failure will be summarised by Kaplan-
Meier curves for each treatment group and compared
overall using the logrank test and survival regression
methods. For secondary outcomes, continuous data will
be reported as differences in means and binary data will
be reported in terms of the relative risk, each with 95%
confidence intervals. Missing data will be monitored and
strategies developed to minimise their occurrence. Miss-
ing data will be handled by considering the robustness
of the complete case analysis in relation to sensitivity
analysis using various imputation assumptions; however,
these analyses will be informed by data collected on the
reasons for missing data.
Economic analysis plan
The cost analysis will be carried out by adopting the per-
spectives of the National Health Service and personal so-
cial service providers and patients, which approximates
a societal perspective. Unit cost data will be obtained
from appropriate sources [57,58], and total costs for
each patient will be calculated.
Two analytic approaches will be used: a within-trial
analysis and an economic model. Trial-based estimates
of cost-effectiveness will be calculated based on standard
methods [59]. Uncertainty in parametric estimates will
be addressed by applying nonparametric bootstrapping
and estimating cost-effectiveness acceptability curves
[59]. We will also apply regression models of cost and
outcomes with age, baseline active anterior uveitis grade
score and other covariates as deemed appropriate to
minimise bias in the estimates of incremental cost-
effectiveness.
A model-based extrapolation of the trial results will be
performed to explore the impact of a longer analytic
time horizon and health outcomes on the treatment
cost-effectiveness [60]. The impact of adalimumab on
the development of cataracts, glaucoma and blindness
will be estimated by constructing risk equations based
on epidemiological data [61,62]. A Markov model of
treatment effect on JIA will be developed with costs and
health state utilities derived from published sources at-
tached to health states to assess the long-term costs and
benefits of the two treatment arms.
Table 1 Study visits and assessmentsa
Time (months)
Randomisation
and
commencement
of treatment
End of
treatment
End
of
trial
Events and assessments Screeningb 0c 1 2 3 6 9 12 15 18 21 24 27 30 33 36 Premature
withdrawal
Written informed consent X
Confirmed consent (verbal) X X X X X X X X X X X X X X
Assessment of eligibility
criteria
X X
Review of medical/
ophthalmic/surgical history
X
Review of concomitant
medications
X X X X X X X X X X X X X X X X X
Pregnancy test (serum) (X) X X X X X X X
Purified protein derivative
tuberculin skin testd/test for
latent TB as locally
performed
X
Urinalysise X X X X X X X X X X X X X X X X
Randomisation X
Study intervention X X X X X X X X X
Compliance with study
intervention
X X X X X X X X X
Physical examination:
complete
X X X X X X X X X X X X X X X X
Vital signs (heart and
respiratory rates,
temperature, blood pressure)
X X X X X X X X X X X X X X X X
Height X X X X X X X X X X X X X X X X
Weight X X X X X X X X X X X X X X X X
Childhood Health
Questionnaire
X X X X X X X X X
Childhood Health
Assessment Questionnaire
X X X X X X X X X
Health Utilities Index Mark 2
questionnaire
X X X X X X X X X
Client Service Receipt
Inventory
X
Sample for DNA collection (X) (X) (X)
RNA and serum/plasma (X) (X) (X)
Haematological analysis X X X X X X X X X X X X X X X X
Biochemical analysis X X X X X X X X X X X X X X X X
Samples for HAHA analysesf X X
ANA, dsDNA and ENA X X
Ophthalmic assessments
Vision assessment X X X X X X X X X X X X X X X X
Optical coherence
tomography (optional)
(X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X)
Assessment of vitritis X X X X X X X X X X X X X X X X
Slit-lamp biomicroscopy X X X X X X X X X X X X X X X X
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Table 1 Study visits and assessmentsa (Continued)
Cataract scoring X X X X X X X X X X X X X X X X
Goldmann tonometry or
Tono-Pen
X X X X X X X X X X X X X X X X
Standard ACR paediatric
core set outcome variables
X X X X X X X X X X X X X X X X
Tanner score X X X X X X X X X X
Review of participant diaries X X X X X X X X X X X X X X X (X)
Assessment of adverse
events
X X X X X X X X X X X X X X X X
aACR, American College of Rheumatology; ANA, antinuclear antibody; dsDNA, double-stranded DNA; ENA, extractable nuclear antigen; HAHA, human
antiadalimumab antibody to adalimumab; TB, tuberculosis; (X), as applicable/indicated/appropriate. bAll procedures should be done before study intervention.
cVisit 0 must be completed and treatment must be commenced within 14 days of the screening visit (10 days for pregnancy test). dParticipants who are
PPD-positive at screening will require a chest X-ray. Treatment of participants who have a positive PPD skin test and/or abnormal chest X-ray should be carried
out in accordance with regional and/or national guidelines and initiated at least 4 weeks prior to the first dose of trial medication. Participants with recent (within
6 months of trial entry screen) positive PPD test (≥5 mm) who are being treated with appropriate prophylaxis may request a waiver for a PPD screening from the
Medicines for Children Research Network Clinical Trials Unit. Documentation of the positive PPD test should be available, as well as chest X-ray reports, from the
date of the positive PPD test and treatment or prophylaxis history from near the time of the participant’s conversion. eMicroscopic urinalysis will be obtained at
baseline and for other visits only if relevant abnormalities greater than trace are noted on the dipstick analysis. fTo be done also as required if anaphylaxis occurs
during trial.
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estimated based on quality-adjusted life-year (QALY)
estimates. Costs and benefits exceeding 1 year will be
discounted at 3.5% per annum in accordance with the
current National Institute for Health and Care Excel-
lence rate [63]. Estimates of ICERs will be compared
with the £20,000 to £30,000 per QALY threshold for
cost-effectiveness [63], and a range of uni- and multi-
variate analyses, as well as probabilistic sensitivity ana-
lyses, will be conducted to assess the robustness of the
analysis.
Trial status
At the time of manuscript submission, this trial was
open at 14 hospital sites and had recruited 58 patients.
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